Evidence map›Paper›PMID 40181481›Full record

ArticleAlzheimer's research & therapy2025

Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer's disease and other neurodegenerative dementias in a large Chinese cohort.

Bin Jiao, Ziyu Ouyang, Yiliang Liu, Cong Zhang, Tianyan Xu, Qijie Yang, Sizhe Zhang, Yuan Zhu, Meidan Wan, Xuewen Xiao and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Synergistic association of insomnia and anxiety with cognitive impairment and dementia in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Utility ofAlzheimer's research & therapy · 2025
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bin JiaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Ziyu OuyangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yiliang LiuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Cong ZhangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Tianyan XuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Qijie YangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Sizhe ZhangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yuan ZhuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Meidan WanDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xuewen XiaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xixi LiuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yafang ZhouDepartment of Geriatrics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xinxin LiaoDepartment of Geriatrics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Weiwei ZhangDepartment of Radiology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Shilin LuoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Lu ShenDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China. shenlu@csu.edu.cn.

Funding

the Hunan Health Commission Grant 20232460the National Key R&D Program of China 2023YFC3603700the National Natural Science Foundation of China No. U22A20300, 82071216, 82371434the Outstanding Youth Fund of Hunan Provincial Natural Science Foundation 2024JJ2097the Science and Technology Major Project of Hunan Province 2021SK1020the STI2030-Major Projects No.2021ZD0201803
6 · The paper itself

Abstract

backgroundEthnic variations and detection methods may lead to differences in diagnostic biomarkers of dementia, and few comparative studies have evaluated the six plasma biomarkers of Alzheimer's disease (AD) and other neurodegenerative dementias in the Chinese population.

methodsA cross-sectional cohort of 668 participants were enrolled, including 245 amnesic mild cognitive impairment (aMCI) or AD patients with Aβ positive pathology, 67 with frontotemporal dementia (FTD), 100 with progressive supranuclear palsy (PSP), 72 with dementia with Lewy bodies (DLB) and 184 healthy controls. Additionally, a longitudinal subset of 19 aMCI and 30 AD patients was followed for an average period of 1 year. Plasma biomarkers, including p-tau181, p-tau217, p-tau231, NfL, GFAP, and α-synuclein, were simultaneously measured using a novel single molecular array method. Aβ42 and p-tau181 levels in CSF, amyloid PET and structural MRI were measured.

resultsPlasma p-tau217 and p-tau231 were most effective in diagnosing aMCI/AD (AUC = 0.95 and 0.93, respectively), while p-tau217, p-tau231 and p-tau181 presented the best differential diagnosis for AD from PSP, FTD and DLB respectively (AUC = 0.84, 0.81 and 0.83). α-synuclein was presented as the best biomarker for PSP variant and behavior variant FTD subtypes (AUC = 0.81 and 0.74, respectively). Among them, p-tau217, p-tau231, GFAP and a-synuclein were negatively correlated with CSF Aβ42/40, while p-tau217 and GFAP were positively correlated with CSF p-tau181. Besides, p-tau181, p-tau217, and GFAP were associated with temporal lobe volume, while p-tau231 and GFAP were associated with frontal lobe volume. Longitudinal analysis showed the higher p-tau181 could predict the cognitive decline progression.

conclusionsThis study validate the practicality of blood biomarkers in the Chinese Han population using a novel single molecule immune detection method. Through the clinical performance study for several biomarkers, we found the plasma p-tau217 was the most effective biomarker in AD diagnosis, and p-tau showed high accuracy for differential diagnosis of AD from other dementia, GFAP is associated with multiple aspects of AD pathology, and frontal and temporal lobe volume, and p-tau181 can reflect the dynamic cognitive decline of AD.

Indexed as

Alzheimer Diseasetau ProteinsAgedAged, 80 and overalpha-SynucleinAmyloid beta-PeptidesBiomarkersChinaCognitive DysfunctionCohort StudiesCross-Sectional StudiesEast Asian PeopleFemaleFrontotemporal DementiaGlial Fibrillary Acidic ProteinHumansalpha-SynucleinAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic ProteinNeurofilament Proteinstau ProteinsAlzheimer’s diseaseGlial fibrillary acidic proteinNeurofilament light chainPhosphorylated-tauPlasma biomarkerα-synuclein

Identifiers

PMID40181481
PMCPMC11969745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.